Wei He1, Mingxin Wang2, Yang Wang3, Qian Wang2, Bin Luo4. 1. Department of Orthopedics, the 305 Hospital of Chinese PLA, Beijing, People's Republic of China. 2. Department of Orthopedics, General Hospital of Chinese Armed Police Forces, Beijing, People's Republic of China. 3. Department of Orthopedics, Changzheng Hospital of Second Military Medical University, Shanghai, People's Republic of China. 4. Department of Orthopedics, People's Hospital of Poyang Country, Jiangxi Province, People's Republic of China.
Abstract
BACKGROUND: The aim is to determine whether CXC chemokine ligand-12 (CXCL12) levels in plasma and synovial fluid (SF) of patients with knee osteoarthritis (OA) are correlated with the disease severity. In addition, we set out to investigate whether a peripheral blood test can avoid aspirating patients to determine CXCL12 levels. METHODS: This study consisted of 244 patients with knee OA and 244 age- and gender-matched healthy controls. Osteoarthritis progression was classified based on Kellgren-Lawrence (KL) by evaluating radiographic changes observed in anteroposterior knee radiography. The CXCL12 levels in the plasma and SF were measured by a quantitative sandwich enzyme-linked immunosorbent assay. RESULTS: Plasma CXCL12 levels were higher in OA patients as compared with controls (P < .0001). There was a positive correlation between levels of CXCL12 and grade (P < .0001). Base on the receiver operating characteristic curve, the optimal cutoff value of plasma CXCL12 levels as an indicator for screening of OA was estimated to be 5.5 ng/mL, which yielded a sensitivity of 78.4% and a specificity of 80.2%, with the area under the curve at 0.850 (95% confidence interval [CI], 0.816-0.889; P < .0001). In multivariate analysis, there was an increased risk of active OA associated with plasma CXCL12 levels ≥10.5 ng/mL (odds ratio, 6.76; 95% CI, 3.88-12.53; P < .0001) after adjusting for possible confounders. Similarly, there was an increased risk of active OA associated with SF CXCL12 levels ≥15.0 ng/mL (odds ratio, 8.45; 95% CI, 3.23-18.22; P < .0001) after adjusting for possible confounders. CONCLUSION: The CXCL12 levels in the plasma and SF may serve as effective biomarkers for the severity of OA.
BACKGROUND: The aim is to determine whether CXC chemokine ligand-12 (CXCL12) levels in plasma and synovial fluid (SF) of patients with knee osteoarthritis (OA) are correlated with the disease severity. In addition, we set out to investigate whether a peripheral blood test can avoid aspirating patients to determine CXCL12 levels. METHODS: This study consisted of 244 patients with knee OA and 244 age- and gender-matched healthy controls. Osteoarthritis progression was classified based on Kellgren-Lawrence (KL) by evaluating radiographic changes observed in anteroposterior knee radiography. The CXCL12 levels in the plasma and SF were measured by a quantitative sandwich enzyme-linked immunosorbent assay. RESULTS: Plasma CXCL12 levels were higher in OA patients as compared with controls (P < .0001). There was a positive correlation between levels of CXCL12 and grade (P < .0001). Base on the receiver operating characteristic curve, the optimal cutoff value of plasma CXCL12 levels as an indicator for screening of OA was estimated to be 5.5 ng/mL, which yielded a sensitivity of 78.4% and a specificity of 80.2%, with the area under the curve at 0.850 (95% confidence interval [CI], 0.816-0.889; P < .0001). In multivariate analysis, there was an increased risk of active OA associated with plasma CXCL12 levels ≥10.5 ng/mL (odds ratio, 6.76; 95% CI, 3.88-12.53; P < .0001) after adjusting for possible confounders. Similarly, there was an increased risk of active OA associated with SF CXCL12 levels ≥15.0 ng/mL (odds ratio, 8.45; 95% CI, 3.23-18.22; P < .0001) after adjusting for possible confounders. CONCLUSION: The CXCL12 levels in the plasma and SF may serve as effective biomarkers for the severity of OA.
Authors: Julia M Scheffler; Karin L Gustafsson; Aidan Barrett; Carmen Corciulo; Christina Drevinge; Alicia M Del Carpio Pons; Piotr Humeniuk; Cecilia Engdahl; Jan-Åke Gustafsson; Claes Ohlsson; Hans Carlsten; Marie K Lagerquist; Ulrika Islander Journal: JBMR Plus Date: 2022-06-17